![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, August 11, 2011 4:35:19 PM
1) They must raise capital and soon. Can't wait until the last minute. This means new shares-it's the only thing they have unless they sell 188 or other intellectual property-which would really hurt share prices. Either way, dilution or a negative hit.
2) Once below a $1 they will get a delisting warning. They cannot risk delisting and be taken seriously. A second reverse split is likely if they cannot sustain over $1.
Just my opinion but I personally am looking for an entry around $.50-.60. I won't touch it above that. Even then I feel a RS announcement will drop is to .30 in one session.
Unless the acquire something there is now no revenue potential (aka no reason the stock would go up) for at least a year. Sure an FDA acceptance for filing of 514 NDA would be a short lived pop.
The one wildcard that actually is more likely now is to try to find a buyer for ANX that it better funded. So anything is possible, but this went from an investment in a biopharm with a bright outlook to a pure high risk spec play.
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM